0001179110-22-000399.txt : 20220111 0001179110-22-000399.hdr.sgml : 20220111 20220111161922 ACCESSION NUMBER: 0001179110-22-000399 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220107 FILED AS OF DATE: 20220111 DATE AS OF CHANGE: 20220111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boulding Mark Elliott CENTRAL INDEX KEY: 0001578852 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 22524112 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 edgar.xml FORM 4 - X0306 4 2022-01-07 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001578852 Boulding Mark Elliott C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 Exec. VP and CLO Common Stock 2022-01-07 4 S 0 885 38.525 D 47489 D Common Stock 2022-01-07 4 A 0 14400 0 A 61889 D Stock Option (Right to Buy) 38.10 2022-01-07 4 A 0 54000 0 A 2032-01-06 Common Stock 54000 54000 D Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs. Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. /s/ Avraham S. Adler, attorney-in-fact 2022-01-11